A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis

Sebastian G. De La Fuente, Jeremiah Deneve, Colin M. Parsons, Jonathan S. Zager, Anthony P. Conley, Ricardo J. Gonzalez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs). Methods Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups. Results Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620). Conclusions Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.

Original languageEnglish (US)
Pages (from-to)655-660
Number of pages6
JournalHPB
Volume15
Issue number9
DOIs
StatePublished - Jan 1 2013

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasm Metastasis
Liver
Survival
Liver Diseases
Protein-Tyrosine Kinases

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. / De La Fuente, Sebastian G.; Deneve, Jeremiah; Parsons, Colin M.; Zager, Jonathan S.; Conley, Anthony P.; Gonzalez, Ricardo J.

In: HPB, Vol. 15, No. 9, 01.01.2013, p. 655-660.

Research output: Contribution to journalArticle

De La Fuente, Sebastian G. ; Deneve, Jeremiah ; Parsons, Colin M. ; Zager, Jonathan S. ; Conley, Anthony P. ; Gonzalez, Ricardo J. / A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. In: HPB. 2013 ; Vol. 15, No. 9. pp. 655-660.
@article{08288b7e379d4203886fde5878415b5a,
title = "A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis",
abstract = "Objectives This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs). Methods Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups. Results Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620). Conclusions Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.",
author = "{De La Fuente}, {Sebastian G.} and Jeremiah Deneve and Parsons, {Colin M.} and Zager, {Jonathan S.} and Conley, {Anthony P.} and Gonzalez, {Ricardo J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/hpb.12011",
language = "English (US)",
volume = "15",
pages = "655--660",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis

AU - De La Fuente, Sebastian G.

AU - Deneve, Jeremiah

AU - Parsons, Colin M.

AU - Zager, Jonathan S.

AU - Conley, Anthony P.

AU - Gonzalez, Ricardo J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objectives This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs). Methods Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups. Results Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620). Conclusions Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.

AB - Objectives This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs). Methods Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups. Results Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620). Conclusions Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.

UR - http://www.scopus.com/inward/record.url?scp=84882449555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882449555&partnerID=8YFLogxK

U2 - 10.1111/hpb.12011

DO - 10.1111/hpb.12011

M3 - Article

VL - 15

SP - 655

EP - 660

JO - HPB

JF - HPB

SN - 1365-182X

IS - 9

ER -